This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Université de Montréal directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $726,750
Cardioprotective effect of a cyclic azapeptide ligand of CD36 against ischemia-reperfusion damage and dysfunction in mice
CIHR · 2021 · Co-investigator
- $1,009,800
Precision medicine study of treatment options in type 2 diabetes patients without cardiovascular disease
CIHR · 2021 · Principal investigator
- $1,800,000
Precision medicine study of type 2 diabetes in the COLCOT-T2D trial
CIHR · 2021 · Principal investigator
Cardioprotective effect of a cyclic azapeptide ligand of CD36 against ischemia-reperfusion damage and dysfunction in mice
Principal investigators: Marleau, Sylvie
Keywords: Azapeptides; Cardiomyocyte; Cardioprotection; Cd36 Receptor; Macrophage; Myocardial Ischemia-Reperfusion
Precision medicine study of treatment options in type 2 diabetes patients without cardiovascular disease
Principal investigators: Dubé, Marie-Pierre; Carpentier, André C; Tardif, Jean-Claude
Keywords: Cardiovascular; Diabetes; Polygenic Scores; Precision Medicine; Prediction Models
Precision medicine study of type 2 diabetes in the COLCOT-T2D trial
Principal investigators: Dubé, Marie-Pierre; Carpentier, André C; Lewis, Gary F; Tardif, Jean-Claude
Keywords: Colchicine; Diabetes; Gender; Genomics; Pharmacogenomics; Proteomics
COLCOT-T2D : Colchicine for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes
Principal investigators: Tardif, Jean-Claude
Keywords: Cancers; Cardiovascular Events; Cognitive Decline; Colchicine; High Risk Cvd Patients; Inflammation; Patient Engagement; Primary Prevention; Randomized Clinical Trial; Type 2 Diabetes
Precision medicine study of type 2 diabetes in the COLCOT-T2D trial
Principal investigators: Dubé, Marie-Pierre; Carpentier, André C; Lewis, Gary F; Tardif, Jean-Claude
Keywords: Clinical Trial; Colchicine; Drug Concentrations; Drug Metabolites; Genomics; Gwas; Pharmacogenomics; Precision Medicine; Proteomics; Type 2 Diabetes
BEhaviors, Therapies, TEchnologies and hypoglycemic Risk in Type 1 diabetes: The BETTER study
Principal investigators: Rabasa-Lhoret, Rémi; Kearns, Patricia A; Brazeau, Anne-Sophie; Carpentier, André C; Dasgupta, Kaberi; Gagnon, Claudia; Henderson, Melanie; Legault, Laurent; Nakhla, Meranda; Perkins, Bruce A
Keywords: Comparative Effectiveness
Investigations of cardiac metabolism using mass isotopomer analysis: A paradigm for biomarker and therapy discovery.
Principal investigators: Des Rosiers, Christine
Keywords: Cardiac Energy Metabolism; Cardiomyopathy; Cgmp Signaling; Diabetes; Heart Perfusion; Mass Spectrometry; Mitochondria; Positron Emission Tomography
Azapeptides: A new class of CD36 ligands for the treatment of ischemic heart disease
Principal investigators: Ong, Huy; Carpentier, André C; Marleau, Sylvie
Keywords: Azapeptides; Cardiac Metabolism; Ischemic Heart Disease
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.